Production Refactoring Method for Pharmaceutical Regulatory Compliance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pharmaceutical companies face challenges in reducing regulatory compliance costs and increasing efficiency while managing risks associated with new Good Manufacturing Practices (GMP) regulations, which can lead to significant revenue loss if any GMP system fails inspection, necessitating a method for production refactoring to optimize profitability.
Innovation Solution
A method and system for production refactoring that quantifies risks and costs associated with regulatory compliance, determines a sequence of actions to minimize revenue at risk and maximize profitability, considering budget constraints, rate of change, and unacceptable actions, using a mixed integer programming approach to optimize production processes and reduce exposure to regulatory risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmaceutical companies implement comprehensive GMP compliance systems to meet FDA regulations, then product quality and regulatory compliance are improved, but total compliance costs increase to as high as 25% of total site operating budget
Solution Approach 1:
The patent segments the production portfolio into different risk categories (high-risk, medium-risk, low-risk products) and applies differentiated compliance strategies to each segment. This allows the company to allocate compliance resources efficiently, focusing intensive compliance efforts on high-risk products while using streamlined processes for low-risk products, thereby reducing overall compliance costs while maintaining required quality standards.
Solution Approach 2:
The patent changes the parameter of compliance intensity by implementing dynamic compliance levels that adjust based on product risk classification. Instead of applying uniform maximum compliance intensity across all products, the system varies compliance parameters (such as inspection frequency, documentation requirements, and process controls) according to each product's risk profile, optimizing the balance between compliance cost and quality assurance.
2Reliability
If a single GMP system fails inspection, then all products produced at the facility may be considered adulterated, but this risk transfer exposes the entire facility's revenue to potential loss from a single product failure
Solution Approach 1:
The patent implements portfolio segmentation that separates products into distinct compliance zones based on risk classification. By structuring the production portfolio into independent compliance segments (different compliance systems or certified locations for different product categories), the company isolates inspection risk to specific segments. This means a failure in one segment does not automatically contaminate the entire facility's products, thereby breaking the risk transfer mechanism that exposes all revenue to single-point failure.
Solution Approach 2:
The patent introduces compliance certification and risk classification as intermediary mechanisms between individual products and the facility-wide GMP system. These intermediaries create buffer zones that prevent direct risk transfer across the entire portfolio. Products with different risk profiles are mediated through different compliance pathways, and certification acts as a shield that protects unrelated products from the consequences of failures in other segments.
3Reliability
If companies redesign production systems to meet new FDA quality by design initiatives, then patient risk management and product quality are improved, but the complexity of production refactoring and supply chain restructuring increases
Solution Approach 1:
The patent applies segmentation by dividing the production system into modular compliance units organized by product risk category. Each segment can be independently designed, implemented, and maintained according to its specific quality requirements. This modular approach reduces overall system complexity by allowing standardized templates for low-risk segments while concentrating customization efforts only where necessary for high-risk segments.
Solution Approach 2:
The patent creates universal compliance frameworks and standardized processes that can be applied across multiple product lines and facilities. By developing multi-functional compliance systems that serve multiple purposes (quality assurance, regulatory compliance, risk management) simultaneously, the patent reduces the need for separate specialized systems, thereby decreasing overall production system complexity while maintaining robust patient risk management capabilities.
Data Source
AI summary
A method for production refactoring of a company comprises quantifying risks stemming from regulations, in particular from an introduction of new regulation. It further comprises identifying actions to take in order to reduce an exposure to risk, quantifying costs of said actions and determining a revenue at risk depending on a revenue and a probability of failure representing said risks. Furthermore, it comprises determining a sequence of actions for solving an improvement problem depending on said revenue at risk and said costs of said actions and profits reducing said revenue at risks and said costs of said actions and increasing said profits.